Ventyx Biosciences, Inc.

2.50 USD
-0.01 (-0.40%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Ventyx Biosciences, Inc. stock is down -42.79% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 June’s closed higher than May. In the last 2 Unusual Options Trades, there were 2 CALLs. 34% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
28 May 18:59 21 Jun, 2024 5.00 CALL 373 4985
29 May 15:02 21 Jun, 2024 5.00 CALL 804 5740

About Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc. develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus.

  • HC Wainwright & Co.
    Thu Jun 13, 06:39
  • Oppenheimer
    Thu Jun 6, 09:30
  • HC Wainwright & Co.
    Thu Jun 6, 06:55